Genmab A/S Announces Expansion Of Duobody Platform Collaboration With Janssen Biotech Inc.
Published: Dec 04, 2013
Copenhagen, Denmark; December 4, 2013 – Genmab A/S (OMX: GEN) announced today an expansion of its collaboration with Janssen Biotech, Inc. (“Janssen”) to create and develop bispecific antibodies using the DuoBody technology platform. The original agreement entitled Janssen to work on up to ten DuoBody programs. Under the terms of the amendment, Janssen is entitled to work on up to ten additional programs.
Help employers find you! Check out all the jobs and post your resume.